JPS6045527A - 血圧降下剤 - Google Patents
血圧降下剤Info
- Publication number
- JPS6045527A JPS6045527A JP58147235A JP14723583A JPS6045527A JP S6045527 A JPS6045527 A JP S6045527A JP 58147235 A JP58147235 A JP 58147235A JP 14723583 A JP14723583 A JP 14723583A JP S6045527 A JPS6045527 A JP S6045527A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- protein polysaccharide
- present
- hypotensor
- krestin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 23
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 23
- 150000004676 glycans Chemical class 0.000 claims abstract description 17
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 17
- 239000005017 polysaccharide Substances 0.000 claims abstract description 17
- 108010001062 polysaccharide-K Proteins 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 238000005199 ultracentrifugation Methods 0.000 claims abstract description 3
- 239000002220 antihypertensive agent Substances 0.000 claims description 12
- 229940030600 antihypertensive agent Drugs 0.000 claims description 9
- 241000221198 Basidiomycota Species 0.000 claims description 3
- 239000012670 alkaline solution Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000000691 measurement method Methods 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 abstract description 20
- 235000001014 amino acid Nutrition 0.000 abstract description 3
- 150000001413 amino acids Chemical class 0.000 abstract description 3
- FYGDTMLNYKFZSV-WFYNLLPOSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,3s,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-WFYNLLPOSA-N 0.000 abstract description 2
- 229920002498 Beta-glucan Polymers 0.000 abstract description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract description 2
- 235000003704 aspartic acid Nutrition 0.000 abstract description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract description 2
- 239000000470 constituent Substances 0.000 abstract description 2
- 241000222355 Trametes versicolor Species 0.000 abstract 2
- 239000003513 alkali Substances 0.000 abstract 1
- 150000001720 carbohydrates Chemical group 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 208000007530 Essential hypertension Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- -1 valine and leucine Chemical class 0.000 description 2
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241001330002 Bambuseae Species 0.000 description 1
- 241000222356 Coriolus Species 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 1
- 229960003602 guanethidine Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Priority Applications (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58147235A JPS6045527A (ja) | 1983-08-11 | 1983-08-11 | 血圧降下剤 |
| DE3448154A DE3448154C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE3448150A DE3448150C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE19843429551 DE3429551A1 (de) | 1983-08-11 | 1984-08-10 | Pharmazeutische zubereitung, die ein glycoprotein enthaelt |
| DE3448153A DE3448153C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE3448151A DE3448151C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE3448149A DE3448149C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE3448152A DE3448152C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE3448155A DE3448155C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE3448148A DE3448148C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE3448144A DE3448144C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| DE3448145A DE3448145C2 (enrdf_load_stackoverflow) | 1983-08-11 | 1984-08-10 | |
| US06/898,900 US4820689A (en) | 1983-08-11 | 1986-08-22 | Pharmaceutical composition containing a glycoprotein |
| US07/285,664 US5008243A (en) | 1983-08-11 | 1988-12-16 | Pharmaceutical composition containing a glycoprotein |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58147235A JPS6045527A (ja) | 1983-08-11 | 1983-08-11 | 血圧降下剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6045527A true JPS6045527A (ja) | 1985-03-12 |
| JPH0331177B2 JPH0331177B2 (enrdf_load_stackoverflow) | 1991-05-02 |
Family
ID=15425626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58147235A Granted JPS6045527A (ja) | 1983-08-11 | 1983-08-11 | 血圧降下剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6045527A (enrdf_load_stackoverflow) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5693610A (en) * | 1994-08-25 | 1997-12-02 | Kureha Chemical Industry Co., Ltd. | Binding agent for growth factor |
| JP2006257007A (ja) * | 2005-03-16 | 2006-09-28 | Nagase & Co Ltd | アンギオテンシン変換酵素阻害剤 |
-
1983
- 1983-08-11 JP JP58147235A patent/JPS6045527A/ja active Granted
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5693610A (en) * | 1994-08-25 | 1997-12-02 | Kureha Chemical Industry Co., Ltd. | Binding agent for growth factor |
| JP2006257007A (ja) * | 2005-03-16 | 2006-09-28 | Nagase & Co Ltd | アンギオテンシン変換酵素阻害剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0331177B2 (enrdf_load_stackoverflow) | 1991-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1045695B1 (en) | Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f 1? to treat peripheral vascular disease | |
| US5929066A (en) | Chromium/biotin treatment of Type II diabetes | |
| USRE39480E1 (en) | Chromium/biotin treatment of type II diabetes | |
| EP0313654B1 (en) | Drug for prophylaxis and treatment of hepatopathy | |
| JPS6045527A (ja) | 血圧降下剤 | |
| KR0171188B1 (ko) | 당뇨병 치료용 제약 조성물 | |
| JPS6045532A (ja) | 血糖降下剤 | |
| US3852454A (en) | Treatment of rheumatoid arthritis | |
| US6475520B1 (en) | Pharmaceutical composition with low toxicity for anti-inflammation and anti-exudation | |
| US4068001A (en) | Method of medical treatment of pancreatic insufficiency | |
| JPS6045530A (ja) | ネフロ−ゼ症候群改善剤 | |
| JPH0361651B2 (enrdf_load_stackoverflow) | ||
| JPS6045528A (ja) | 虚血性脳疾患改善剤 | |
| JPS6045529A (ja) | 抗血栓症剤 | |
| JPS6045524A (ja) | 抗炎症剤 | |
| JPS6045526A (ja) | 虚血性心疾患改善剤 | |
| KR970005325B1 (ko) | 에이즈 발병방지, 치료제 및 그 치료용 조성물 | |
| JPS6045523A (ja) | 解熱鎮痛剤 | |
| JPH0326173B2 (enrdf_load_stackoverflow) | ||
| JPS6045533A (ja) | プロスタグランジン調節剤 | |
| AU2002302012B2 (en) | Chromim/biotin treatment of type II diabetes | |
| KR940006324B1 (ko) | 항류머티스제 | |
| US5861384A (en) | Immunosuppressive-activity potentiating compositions | |
| JPH0283321A (ja) | 膵臓疾患治療剤 | |
| JPH05345726A (ja) | 蛋白多糖体を含有する抗脱毛症剤 |